Compare KVHI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | ALXO |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.4M | 240.8M |
| IPO Year | 1996 | 2020 |
| Metric | KVHI | ALXO |
|---|---|---|
| Price | $11.55 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 146.1K | ★ 698.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | 26.36 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $9,622,000.00 | N/A |
| Revenue This Year | $28.90 | N/A |
| Revenue Next Year | $31.85 | N/A |
| P/E Ratio | $358.00 | ★ N/A |
| Revenue Growth | ★ 3.82 | N/A |
| 52 Week Low | $5.09 | $0.41 |
| 52 Week High | $11.45 | $2.66 |
| Indicator | KVHI | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 66.97 | 54.37 |
| Support Level | $5.56 | $1.44 |
| Resistance Level | N/A | $2.27 |
| Average True Range (ATR) | 0.79 | 0.14 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 96.97 | 52.94 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.